Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Cantor Fitzgerald

Key Points

• Supernus Pharmaceuticals has been upgraded from a "neutral" to an "overweight" rating by Cantor Fitzgerald, with a target price of $42.00, suggesting a potential upside of 25.56% from its current stock price.
• In contrast, Wall Street Zen recently downgraded the company from a "buy" to a "hold" rating, indicating mixed sentiment among analysts.
• The stock opened at $33.45 and has a market capitalization of $1.87 billion, with a P/E ratio of 30.14.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating in a report issued on Wednesday, Marketbeat reports. The brokerage currently has a $42.00 price target on the specialty pharmaceutical company's stock. Cantor Fitzgerald's target price indicates a potential upside of 18.28% from the company's previous close.

Separately, Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 20th.

Supernus Pharmaceuticals Stock Up 1.2%

Shares of SUPN traded up $0.41 during mid-day trading on Wednesday, reaching $35.51. The company had a trading volume of 858,699 shares, compared to its average volume of 798,286. Supernus Pharmaceuticals has a 52-week low of $27.05 and a 52-week high of $40.28. The stock has a market capitalization of $1.99 billion, a P/E ratio of 31.99 and a beta of 0.74. The stock has a 50 day moving average of $32.64 and a two-hundred day moving average of $33.34.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after acquiring an additional 22,852 shares in the last quarter. Armistice Capital LLC raised its stake in Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after buying an additional 360,000 shares in the last quarter. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock valued at $54,633,000 after buying an additional 28,517 shares in the last quarter. GW&K Investment Management LLC raised its stake in Supernus Pharmaceuticals by 14.6% in the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after buying an additional 176,091 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after buying an additional 110,867 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.